U.S. markets closed

Galmed Pharmaceuticals Ltd. (GLMD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.6100-0.1400 (-5.09%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close2.7500
Open2.7550
Bid2.5600 x 1100
Ask2.6300 x 800
Day's Range2.5500 - 2.7550
52 Week Range2.1500 - 6.2500
Volume83,118
Avg. Volume277,944
Market Cap65.469M
Beta (5Y Monthly)2.19
PE Ratio (TTM)N/A
EPS (TTM)-1.4480
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why Is Penny Stock Galmed Pharma A “Strong Buy” With Triple-Digit Upside?
    TipRanks

    Why Is Penny Stock Galmed Pharma A “Strong Buy” With Triple-Digit Upside?

    Galmed Pharmaceuticals (GLMD) is a clinical-stage biopharmaceutical company focused on developing Aramchol, a stearoyl-coenzyme A desaturase‑1 (SCD1) modulator that targets the liver. Aramchol is a novel oral therapy for the treatment of Non-alcoholic Steatohepatitis (NASH), a type of fatty liver disease and fibrosis. The company, in collaboration with the Hebrew University, is also developing Amilo-5MER, a 5 amino acid synthetic peptide. Synthetic peptides, when bound to a carrier protein, can

  • Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results
    PR Newswire

    Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results

    Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, reports financial results for the three months ended March 31, 2021. The Company will host a conference call and webcast at 08:30 ET today.

  • ACCESSWIRE

    Galmed Pharmaceuticals Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 13, 2021 / Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 8:30 AM Eastern Time.